Copyright Reports & Markets. All rights reserved.

Global α-blocker Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 α-blocker Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global α-blocker Market Size Growth Rate by Product
      • 1.4.2 Non-selective Antagonists
      • 1.4.3 Selective Antagonists
    • 1.5 Market by End User
      • 1.5.1 Global α-blocker Market Size Growth Rate by End User
      • 1.5.2 Hypertension
      • 1.5.3 Raynaud's Disease
      • 1.5.4 Erectile Dysfunction
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global α-blocker Market Size
      • 2.1.1 Global α-blocker Revenue 2014-2025
      • 2.1.2 Global α-blocker Sales 2014-2025
    • 2.2 α-blocker Growth Rate by Regions
      • 2.2.1 Global α-blocker Sales by Regions
      • 2.2.2 Global α-blocker Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 α-blocker Sales by Manufacturers
      • 3.1.1 α-blocker Sales by Manufacturers
      • 3.1.2 α-blocker Sales Market Share by Manufacturers
      • 3.1.3 Global α-blocker Market Concentration Ratio (CR5 and HHI)
    • 3.2 α-blocker Revenue by Manufacturers
      • 3.2.1 α-blocker Revenue by Manufacturers (2014-2019)
      • 3.2.2 α-blocker Revenue Share by Manufacturers (2014-2019)
    • 3.3 α-blocker Price by Manufacturers
    • 3.4 α-blocker Manufacturing Base Distribution, Product Types
      • 3.4.1 α-blocker Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers α-blocker Product Type
      • 3.4.3 Date of International Manufacturers Enter into α-blocker Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global α-blocker Sales by Product
    • 4.2 Global α-blocker Revenue by Product
    • 4.3 α-blocker Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global α-blocker Breakdown Data by End User

    6 North America

    • 6.1 North America α-blocker by Countries
      • 6.1.1 North America α-blocker Sales by Countries
      • 6.1.2 North America α-blocker Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America α-blocker by Product
    • 6.3 North America α-blocker by End User

    7 Europe

    • 7.1 Europe α-blocker by Countries
      • 7.1.1 Europe α-blocker Sales by Countries
      • 7.1.2 Europe α-blocker Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe α-blocker by Product
    • 7.3 Europe α-blocker by End User

    8 Asia Pacific

    • 8.1 Asia Pacific α-blocker by Countries
      • 8.1.1 Asia Pacific α-blocker Sales by Countries
      • 8.1.2 Asia Pacific α-blocker Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific α-blocker by Product
    • 8.3 Asia Pacific α-blocker by End User

    9 Central & South America

    • 9.1 Central & South America α-blocker by Countries
      • 9.1.1 Central & South America α-blocker Sales by Countries
      • 9.1.2 Central & South America α-blocker Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America α-blocker by Product
    • 9.3 Central & South America α-blocker by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa α-blocker by Countries
      • 10.1.1 Middle East and Africa α-blocker Sales by Countries
      • 10.1.2 Middle East and Africa α-blocker Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa α-blocker by Product
    • 10.3 Middle East and Africa α-blocker by End User

    11 Company Profiles

    • 11.1 Pfizer
      • 11.1.1 Pfizer Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Pfizer α-blocker Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Pfizer α-blocker Products Offered
      • 11.1.5 Pfizer Recent Development
    • 11.2 Novartis
      • 11.2.1 Novartis Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Novartis α-blocker Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Novartis α-blocker Products Offered
      • 11.2.5 Novartis Recent Development
    • 11.3 Merck
      • 11.3.1 Merck Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Merck α-blocker Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Merck α-blocker Products Offered
      • 11.3.5 Merck Recent Development
    • 11.4 Astra Zeneca
      • 11.4.1 Astra Zeneca Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Astra Zeneca α-blocker Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Astra Zeneca α-blocker Products Offered
      • 11.4.5 Astra Zeneca Recent Development
    • 11.5 Jhonson and Johnson
      • 11.5.1 Jhonson and Johnson Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Jhonson and Johnson α-blocker Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Jhonson and Johnson α-blocker Products Offered
      • 11.5.5 Jhonson and Johnson Recent Development
    • 11.6 Eli Lilly
      • 11.6.1 Eli Lilly Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Eli Lilly α-blocker Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Eli Lilly α-blocker Products Offered
      • 11.6.5 Eli Lilly Recent Development
    • 11.7 Sanofi
      • 11.7.1 Sanofi Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Sanofi α-blocker Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Sanofi α-blocker Products Offered
      • 11.7.5 Sanofi Recent Development
    • 11.8 Bristol-Myers Squibb
      • 11.8.1 Bristol-Myers Squibb Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Bristol-Myers Squibb α-blocker Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Bristol-Myers Squibb α-blocker Products Offered
      • 11.8.5 Bristol-Myers Squibb Recent Development
    • 11.9 Bayer
      • 11.9.1 Bayer Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Bayer α-blocker Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Bayer α-blocker Products Offered
      • 11.9.5 Bayer Recent Development
    • 11.10 GSK
      • 11.10.1 GSK Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 GSK α-blocker Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 GSK α-blocker Products Offered
      • 11.10.5 GSK Recent Development
    • 11.11 Teva Pharmaceutical

    12 Future Forecast

    • 12.1 α-blocker Market Forecast by Regions
      • 12.1.1 Global α-blocker Sales Forecast by Regions 2019-2025
      • 12.1.2 Global α-blocker Revenue Forecast by Regions 2019-2025
    • 12.2 α-blocker Market Forecast by Product
      • 12.2.1 Global α-blocker Sales Forecast by Product 2019-2025
      • 12.2.2 Global α-blocker Revenue Forecast by Product 2019-2025
    • 12.3 α-blocker Market Forecast by End User
    • 12.4 North America α-blocker Forecast
    • 12.5 Europe α-blocker Forecast
    • 12.6 Asia Pacific α-blocker Forecast
    • 12.7 Central & South America α-blocker Forecast
    • 12.8 Middle East and Africa α-blocker Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 α-blocker Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      α-blockers or α-adrenoreceptor antagonists, are a class of pharmacological agents that act as antagonists on α-adrenergic receptors (α-adrenoceptors).
      The global α-blocker market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the α-blocker market based on company, product type, end user and key regions.

      This report studies the global market size of α-blocker in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of α-blocker in these regions.
      This research report categorizes the global α-blocker market by top players/brands, region, type and end user. This report also studies the global α-blocker market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Pfizer
      Novartis
      Merck
      Astra Zeneca
      Jhonson and Johnson
      Eli Lilly
      Sanofi
      Bristol-Myers Squibb
      Bayer
      GSK
      Teva Pharmaceutical

      Market size by Product
      Non-selective Antagonists
      Selective Antagonists
      Market size by End User
      Hypertension
      Raynaud's Disease
      Erectile Dysfunction

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global α-blocker market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of α-blocker market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global α-blocker companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of α-blocker submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of α-blocker are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of α-blocker market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now